Genmab — Maj 2014
-
dejligt at vi er over 220 inden ASCO
-
Kan vi slutte året over 250 vil jeg mene det er fint. Så er banen kridtet på til 2015 som jeg tror bliver helt vildt med potentiel NDA og approval for Daratumumab
-
vi kan ikke få phase III data på ASCO.. Det første phase III studie er ikke engang startet med at indrulle patienter endnu
-
I det mest optimistiske scenarie får vi pivotal data fra phase II BTD studiet ultimo 2014 og så en NDA filing engang i første halvdel af 2015
-
Nordea går satme også til den
-
Det er nok Novods kommentar om at Dara alene potentielt kan være over 400 kurspoint værd
-
217 så vi er i +
-
-
So just focusing on daratumumab first, that antibody is now really moving forward in Phase III studies now actually as I speak, having completed very quick Phase I and II development, recognizing that the early Phase I of development to the antibody was necessarily very slow because this is a first-in-man experience
-
So based upon that, we are now accelerating very quickly and we have combinations of dara with lenalidomide, combinations of dara coming forward now with bortezomib, and basically there will be combinations of dara with lenalidomide and bortezomib, the so-called RVD plus dara, and these will be very powerful platforms for future treatment.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind